Current Report Filing (8-k)
05 Juni 2019 - 11:23PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 5, 2019
AVID BIOSERVICES, INC.
(Exact name of registrant as specified in
its charter)
|
Delaware
|
|
001-32839
|
|
95-3698422
|
(State of other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
2642 Michelle Drive, Suite 200, Tustin, California 92780
|
|
(Address of Principal Executive Offices)
|
|
|
|
|
|
|
|
Registrant’s telephone number, including area code:
(714) 508-6100
|
|
|
|
______________________________________________________________
|
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
o
|
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant
to Section 12(b) of the Act:
|
Title of each Class
|
Trading Symbol
|
Name of each exchange on which registered
|
|
Common Stock ($0.001
par value per share)
|
CDMO
|
The NASDAQ Stock Market LLC
|
|
Preferred Stock Purchase Rights
|
|
|
|
10.50% Series E Convertible Preferred Stock($0.001 par value per share)
|
CDMOP
|
The NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933(
§
230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (
§
240.12b-2
of this chapter).
o
Emerging growth company
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
o
On June 5, 2019, Avid
Bioservices, Inc. (the “Company”) issued a press release announcing the declaration by the Company’s Board of
Directors of a quarterly cash dividend payment of $0.65625 per share (the “Dividend”) on the Company’s 10.50%
Series E Convertible Preferred Stock (the “Series E Preferred Stock”), accruing from April 1, 2019 through June 30,
2019. The Dividend equates to an annualized 10.50% per share of Series E Preferred Stock based on the $25.00 per share stated liquidation
preference. The Dividend on the Series E Preferred Stock is payable on July 1, 2019 to holders of record at the close of business
on June 17, 2019. A copy of the press release is filed hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following material is
filed as an exhibit to this Current Report on Form 8-K:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
AVID BIOSERVICES, INC.
|
|
|
|
|
|
|
|
|
|
|
Date: June 5, 2019
|
By:
/s/ Daniel R. Hart
|
|
|
Daniel R. Hart
|
|
|
Chief Financial Officer
|
EXHIBIT INDEX
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
